

## List of participants

**N. Joan Abbott**, Blood-Brain Barrier Group, Wolfson Centre for Age Related Diseases, King's College, Hodgkin Building - Guy's Campus, SE1 1UL London, United Kingdom  
Email: joan.abbott@kcl.ac.uk

**J. (Hans) M. Aerts**, Department of Biochemistry, Academic Medical Center (K1-157), Univ. of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands  
Email: j.m.aerts@amc.uva.nl

**José Manuel Baeyens**, Departamento de Farmacología y de Terapéutica, Facultad Medicina, Universidad de Granada, Avda. de Madrid s/n, 18012 Granada, Spain  
Email: jbaeyens@goliat.ugr.es

**Fèlix Bosch**, Esteve Foundation, Llobet i Vall-Llosera 2, 08032 Barcelona, Spain  
Email: fbosch@esteve.org

**Albertus G. de Boer**, BBB Research Group, Division of Pharmacology, LACDR - University of Leiden, Einsteinweg 55, 2300 RA Leiden, The Netherlands  
Email: B.Boer@LACDR.LeidenUniv.NL

**Patrick du Souich**, Département de Pharmacologie, Faculté Médecine. Université de Montréal, Case Postale 6128 succ. "Centre Ville", PQ H3C 3J7 Montréal, Canada  
Email: dusouichp@ere.umontreal.ca

**Sergio Erill**, Esteve Foundation, Llobet i Vall-Llosera 2, 08032 Barcelona, Spain  
Email: serill@esteve.org

**Gert Fricker**, Institut für Pharmazeutische Technologie und Biopharmazie, Im Neuenheimer Feld 366, 69120 Heidelberg, Germany  
Email: jw3@ix.urz.uni-heidelberg.de

**Reinhard Gabathuler**, AngioChem Inc., 550, Sherbrooke Ouest, suite 100, Montreal, Quebec H3A 1B9, Canada  
Email: rgaba@videotron.ca

**Pieter J. Gaillard**, to-BBB technologies BV, Bio-Science Park Leiden, Gorlaeus Laboratories, LACDR-Pharmacology, Einsteinweg 55, 2333 CC Leiden, The Netherlands  
Email: gaillard@toBBB.com

**Hans-Joachim Galla**, Institut für Biochemie, Westfälische Wilhelms-Universität Münster, Wilhelm-Klemm-Strasse 2, D-48149 Münster, Germany  
Email: gallah@uni-muenster.de

**Jörg Kreuter**, Institut für Pharmazeutische Technologie, Johann Wolfgang Goethe-Universität, Marie-Curie-Strabe 9, Biozentrum, D-60439 Frankfurt am Main, Germany  
Email: kreuter@em.uni-frankfurt.de

**Hermann Lage**, Institut für Pathologie, Humboldt-University Berlin, Charité Campus Mitte - Schumannstr. 20/21, D-10117 Berlin, Germany  
Email: hermann.lage@charite.de

**J(Hans) P. Langedijk**, Pepsican Systems B.V., Edelhertweg 15, P.O. Box 2098, 8203 AB Lelystad, The Netherlands

Email: [j.p.m.langedijk@pepsican.nl](mailto:j.p.m.langedijk@pepsican.nl)

**Michel Lemaire**, Novartis Pharma AG, ECD-Pharmacokinetic Nervous System, CH-4001 Basel, Switzerland

Email: [michel.lemaire@pharma.novartis.com](mailto:michel.lemaire@pharma.novartis.com)

**Stephen McQuaid**, Neuropathology Laboratory, Royal Group of Hospitals Trust, Queens University of Belfast, Belfast, Northern Ireland

Email: [s.mcquaid@qub.ac.uk](mailto:s.mcquaid@qub.ac.uk)

**Alfred N. Nijkerk**, to-BBB technologies BV, Bio-Science Park, Gorlaeus Lab., Einsteinweg 55, 2333 CC Leiden, The Netherlands

Email: [Nijkerk@toBBB.com](mailto:Nijkerk@toBBB.com)

**William M. Pardridge**, UCLA, Warren Hall 13-164, 900 Veteran Avenue, CA 90024 Los Angeles, USA

Email: [wpardridge@mednet.ucla.edu](mailto:wpardridge@mednet.ucla.edu)

**Jean-Michel Scherrmann**, INSERM U26, Hôpital Fernand Widal, 200, rue du Faubourg Saint-Denis, 75475-Cedex 10 Paris, France

Email: [jean-michel.scherrmann@fwidal.inserm.fr](mailto:jean-michel.scherrmann@fwidal.inserm.fr)

**Quentin R. Smith**, Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, TX 79106 Amarillo, USA

Email: [quentin.smith@ttuhsc.edu](mailto:quentin.smith@ttuhsc.edu)

**Danica Stanimirovic**, Institute for Biological Sciences, National Research Council of Canada, 1200 Montreal Road, Bldg. M-54, ON K1A 0R6 Ottawa, Canada

Email: [danica.stanimirovic@nrc-cnrc.gc.ca](mailto:danica.stanimirovic@nrc-cnrc.gc.ca)

**Yuichi Sugiyama**, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, 113-0033 Tokyo, Japan

Email: [yu-one.sugiyama@nifty.com](mailto:yu-one.sugiyama@nifty.com)

**Akira Tsuji**, Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, 920-1192 Kanazawa, Japan

Email: [tsuji@kenroku.kanazawa-u.ac.jp](mailto:tsuji@kenroku.kanazawa-u.ac.jp)

**Olaf van Tellingen**, Department of Diagnostic Oncology, Antoni van Leeuwenhoek ziekenhuis, Nederlands Kanker Instituut, Plesmanlaan, 121, 1066 CX Amsterdam, The Netherlands

Email: [o.v.tellingen@nki.nl](mailto:o.v.tellingen@nki.nl)

**Jan S.A. Verlooy**, Department of Neurosurgery, University Hospital Antwerp, Wilrijkstraat 10, 2610 Edegem, Belgium

Email: [Jan.Verlooy@uza.be](mailto:Jan.Verlooy@uza.be)

**Ian R. Whittle**, Division of Clinical Neurosciences, Western General Hospital, Crewe Road, EH4 2XU Edinburgh, United Kingdom

Email: [irw@skull.dcn.ed.ac.uk](mailto:irw@skull.dcn.ed.ac.uk)